| P50 | author | Julia Gee | Q42700685 |
| | Peter Barrett-Lee | Q56446934 |
| | Steve E Hiscox | Q58121370 |
| P2093 | author name string | Chris Smith | |
| | Robert I Nicholson | |
| | Zaruhi Poghosyan | |
| | Lindy Goddard | |
| | Nicola Jordan | |
| | Rebecca Bellerby | |
| | Bedanta Baruha | |
| P2860 | cites work | Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth | Q28199263 |
| | CD44: from adhesion molecules to signalling regulators | Q28201701 |
| | Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 |
| | Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 |
| | CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression | Q34627193 |
| | In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. | Q34711966 |
| | Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells | Q35128711 |
| | Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials | Q35186747 |
| | Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival | Q35745456 |
| | CD44 is required for two consecutive steps in HGF/c-Met signaling. | Q35805198 |
| | Hyaluronan: from extracellular glue to pericellular cue. | Q35824079 |
| | The cytoplasmic tail of CD44 is required for basolateral localization in epithelial MDCK cells but does not mediate association with the detergent-insoluble cytoskeleton of fibroblasts | Q36233014 |
| | Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. | Q36236568 |
| | Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. | Q36236645 |
| | Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells | Q36393289 |
| | Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. | Q36641814 |
| | Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer | Q36720699 |
| | Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. | Q36814491 |
| | Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression | Q37152303 |
| | Expression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3-kinase/Akt survival pathway in tamoxifen resistant breast cancer cells. | Q37345203 |
| | Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts | Q37456491 |
| | Therapeutic targeting of tumor-stroma interactions. | Q37851151 |
| | RHAMM/ERK interaction induces proliferative activities of cementifying fibroma cells through a mechanism based on the CD44-EGFR. | Q38340025 |
| | Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically | Q38419620 |
| | CD44 expression is associated with increased survival in node-negative invasive breast carcinoma | Q38442970 |
| | Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. | Q39403553 |
| | ErbB3(80 kDa), a nuclear variant of the ErbB3 receptor, binds to the Cyclin D1 promoter to activate cell proliferation but is negatively controlled by p14ARF. | Q39409637 |
| | ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome | Q39417011 |
| | Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype | Q39523158 |
| | Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells | Q39570673 |
| | Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo | Q39579117 |
| | A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. | Q39796335 |
| | Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. | Q39891252 |
| | Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity | Q39913505 |
| | Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities | Q39919533 |
| | DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. | Q39970405 |
| | EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. | Q40013006 |
| | Akt- and MAPK-mediated activation and secretion of MMP-9 into stroma in breast cancer cells upon heregulin treatment. | Q40029865 |
| | CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis | Q40072858 |
| | Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration | Q40134433 |
| | Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. | Q40396869 |
| | c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. | Q40472507 |
| | Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). | Q40512067 |
| | Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells | Q40670668 |
| | Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells | Q40714989 |
| | Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation | Q41083579 |
| | Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells | Q41843755 |
| | Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology | Q41983563 |
| | Hyaluronan facilitates transforming growth factor-β1-dependent proliferation via CD44 and epidermal growth factor receptor interaction | Q42733192 |
| | A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer | Q44613177 |
| | A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer | Q45249576 |
| | The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study | Q46478443 |
| | Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. | Q46634459 |
| | Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer | Q46935004 |
| | Co-Expression of ErbB-Family Members in Human Breast Cancer: Her-2/neu is the Preferred Dimerization Candidate in Nodal-positive Tumors | Q53375722 |
| | Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. | Q54568061 |
| | CD44 Regulates Hepatocyte Growth Factor-mediated Vascular Integrity | Q57372712 |
| | Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas | Q58212424 |
| | Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy | Q62690767 |
| | Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia | Q73669240 |
| | Binding specificities and affinities of egf domains for ErbB receptors | Q77360929 |
| | Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors | Q83328070 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tamoxifen | Q412178 |
| | overexpression | Q61643320 |
| P304 | page(s) | 458 | |
| P577 | publication date | 2012-10-06 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan | |
| P478 | volume | 12 | |